{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:41:47Z","timestamp":1789872107665,"version":"4.0.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T00:00:00Z","timestamp":1490572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T00:00:00Z","timestamp":1490572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A key challenge in the field of therapeutic viral vector\/vaccine manufacturing is maximizing production. For most vector platforms, the \u2018benchmark\u2019 vector titres are achieved with inert reporter genes. However, expression of therapeutic transgenes can often adversely affect vector titres due to biological effects on cell metabolism and\/or on the vector virion itself. Here, we exemplify the novel \u2018Transgene Repression In vector Production\u2019 (TRiP) system for the production of both RNA- and DNA-based viral vectors. The TRiP system utilizes a translational block of one or more transgenes by employing the bacterial tryptophan RNA-binding attenuation protein (TRAP), which binds its target RNA sequence close to the transgene initiation codon. We report enhancement of titres of lentiviral vectors expressing Cyclo-oxygenase-2 by 600-fold, and adenoviral vectors expressing the pro-apoptotic gene Bax by &gt;150,000-fold. The TRiP system is transgene-independent and will be a particularly useful platform in the clinical development of viral vectors expressing problematic transgenes.<\/jats:p>","DOI":"10.1038\/ncomms14834","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T05:33:23Z","timestamp":1490592803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Enhancing titres of therapeutic viral vectors using the transgene repression in vector production (TRiP) system"],"prefix":"10.1038","volume":"8","author":[{"given":"H. E.","family":"Maunder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. R.","family":"Kolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. R.","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. T.","family":"Mkandawire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tatoris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Iqball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Devarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Lad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. G.","family":"Clarkson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. A.","family":"Mitrophanous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. C.","family":"Farley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,27]]},"reference":[{"key":"BFncomms14834_CR1","unstructured":"Muhlebach, M. D. et al. in Retroviruses: Molecular Biology, Genomics and Pathogenesis (eds Kurth, R. and Bannert, N.) Ch. 13, 347\u2013370Caister Academic Press (2010)."},{"key":"BFncomms14834_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1089\/hum.2013.062","volume":"24","author":"MN Antoniou","year":"2013","unstructured":"Antoniou, M. N., Skipper, K. A. & Anakok, O. Optimizing retroviral gene expression for effective therapies. Hum. Gene Ther. 24, 363\u2013374 (2013).","journal-title":"Hum. Gene Ther."},{"key":"BFncomms14834_CR3","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3390\/v6020832","volume":"6","author":"C Capasso","year":"2014","unstructured":"Capasso, C. et al. The evolution of adenoviral vectors through genetic and chemical surface modifications. Viruses 6, 832\u2013855 (2014).","journal-title":"Viruses"},{"key":"BFncomms14834_CR4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrg3742","volume":"15","author":"MA Kotterman","year":"2014","unstructured":"Kotterman, M. A. & Schaffer, D. V. Engineering adeno-associated viruses for clinical gene therapy. Nat. Rev. Genet. 15, 445\u2013451 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"BFncomms14834_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/PPO.0000000000000033","volume":"20","author":"RA Morgan","year":"2014","unstructured":"Morgan, R. A. & Kakarla, S. Genetic modification of T cells. Cancer J. 20, 145\u2013150 (2014).","journal-title":"Cancer J."},{"key":"BFncomms14834_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1517\/14712598.2014.895811","volume":"14","author":"F Touzot","year":"2014","unstructured":"Touzot, F., Hacein-Bey-Abina, S., Fischer, A. & Cavazzana, M. Gene therapy for inherited immunodeficiency. Expert Opin. Biol. Ther. 14, 789\u2013798 (2014).","journal-title":"Expert Opin. Biol. Ther."},{"key":"BFncomms14834_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/gt.2011.153","volume":"19","author":"KS Balaggan","year":"2012","unstructured":"Balaggan, K. S. & Ali, R. R. Ocular gene delivery using lentiviral vectors. Gene Ther. 19, 145\u2013153 (2012).","journal-title":"Gene Ther."},{"key":"BFncomms14834_CR8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1089\/hum.2013.2517","volume":"24","author":"MG Katz","year":"2013","unstructured":"Katz, M. G. et al. Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: current concepts and future applications. Hum. Gene Ther. 24, 914\u2013927 (2013).","journal-title":"Hum. Gene Ther."},{"key":"BFncomms14834_CR9","doi-asserted-by":"publisher","first-page":"a009431","DOI":"10.1101\/cshperspect.a009431","volume":"2","author":"PG Coune","year":"2012","unstructured":"Coune, P. G., Schneider, B. L. & Aebischer, P. Parkinson\u2019s disease: gene therapies. Cold Spring Harb. Perspect. Med. 2, a009431 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"BFncomms14834_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/978-1-4471-6458-6_13","volume":"818","author":"E Pazarentzos","year":"2014","unstructured":"Pazarentzos, E. & Mazarakis, N. D. Anticancer gene transfer for cancer gene therapy. Adv. Exp. Med. Biol. 818, 255\u2013280 (2014).","journal-title":"Adv. Exp. Med. Biol."},{"key":"BFncomms14834_CR11","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.3390\/v6072735","volume":"6","author":"AF Altenburg","year":"2014","unstructured":"Altenburg, A. F. et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 6, 2735\u20132761 (2014).","journal-title":"Viruses"},{"key":"BFncomms14834_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/978-1-59745-561-9_30","volume":"542","author":"V Schirrmacher","year":"2009","unstructured":"Schirrmacher, V. & Fournier, P. Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol. Biol. 542, 565\u2013605 (2009).","journal-title":"Methods Mol. Biol."},{"key":"BFncomms14834_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2174\/1566523044578077","volume":"4","author":"ED Papadakis","year":"2004","unstructured":"Papadakis, E. D., Nicklin, S. A., Baker, A. H. & White, S. J. Promoters and control elements: designing expression cassettes for gene therapy. Curr. Gene Ther. 4, 89\u2013113 (2004).","journal-title":"Curr. Gene Ther."},{"key":"BFncomms14834_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/sj.gt.3303080","volume":"15","author":"PA Radcliffe","year":"2008","unstructured":"Radcliffe, P. A. et al. Analysis of factor VIII mediated suppression of lentiviral vector titers. Gene Ther. 15, 289\u2013297 (2008).","journal-title":"Gene Ther."},{"key":"BFncomms14834_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev.genet.39.073003.093745","volume":"39","author":"P Gollnick","year":"2005","unstructured":"Gollnick, P., Babitzke, P., Antson, A. & Yanofsky, C. Complexity in regulation of tryptophan biosynthesis in Bacillus subtilis. Annu. Rev. Genet. 39, 47\u201368 (2005).","journal-title":"Annu. Rev. Genet."},{"key":"BFncomms14834_CR16","doi-asserted-by":"crossref","first-page":"16597","DOI":"10.1016\/S0021-9258(19)89431-0","volume":"269","author":"P Babitzke","year":"1994","unstructured":"Babitzke, P., Stults, J. T., Shire, S. J. & Yanofsky, C. TRAP, the trp RNA-binding attenuation protein of Bacillus subtilis, is a multisubunit complex that appears to recognize G\/UAG repeats in the trpEDCFBA and trpG transcripts. J. Biol. Chem. 269, 16597\u201316604 (1994).","journal-title":"J. Biol. Chem."},{"key":"BFncomms14834_CR17","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.1128\/jb.178.17.5159-5163.1996","volume":"178","author":"P Babitzke","year":"1996","unstructured":"Babitzke, P., Yealy, J. & Campanelli, D. Interaction of the trp RNA-Binding attenuation protein (TRAP) of Bacillus subtilis with RNA: effects of the number of GAG repeats, the nucleotides separating adjacent repeats, and RNA secondary structure. J. Bacteriol. 178, 5159\u20135163 (1996).","journal-title":"J. Bacteriol."},{"key":"BFncomms14834_CR18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1017\/S1355838299991057","volume":"5","author":"MB Elliot","year":"1999","unstructured":"Elliot, M. B., Gottlieb, P. A. & Gollnick, P. Probing the TRAP-RNA interaction with nucleoside analogs. RNA 5, 1277\u20131289 (1999).","journal-title":"RNA"},{"key":"BFncomms14834_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-1-4939-2214-7_20","volume":"259","author":"NM McAdams","year":"2015","unstructured":"McAdams, N. M. & Gollnick, P. Characterization of TRAP-mediated regulation of the B. subtilis trp operon using in vitro transcription and transcriptional reporter fusions in vivo. Methods Mol. Biol. 259, 333\u2013347 (2015).","journal-title":"Methods Mol. Biol."},{"key":"BFncomms14834_CR20","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.1093\/nar\/gkl584","volume":"34","author":"M Nie","year":"2006","unstructured":"Nie, M. & Htun, H. Different modes and potencies of translational repression by sequence-specific RNA-protein interaction at the 5\u2032-UTR. Nucleic Acids Res. 34, 5528\u20135540 (2006).","journal-title":"Nucleic Acids Res."},{"key":"BFncomms14834_CR21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1096\/fj.04-3180fje","volume":"19","author":"MR Soboleski","year":"2005","unstructured":"Soboleski, M. R., Oaks, J. & Halford, W. P. Green fluorescent protein is a quantitative reporter of gene expression in individual eukaryotic cells. FASEB J. 19, 440\u2013442 (2005).","journal-title":"FASEB J."},{"key":"BFncomms14834_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4155\/pbp.14.16","volume":"2","author":"O-W Merten","year":"2014","unstructured":"Merten, O.-W., Schweizer, M., Chahal, P. & Kamen, A. A. Manufacturing of viral vectors for gene therapy: part I. Upstream processing. Pharmaceut. Bioprocess. 2, 183\u2013203 (2014).","journal-title":"Pharmaceut. Bioprocess."},{"key":"BFncomms14834_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ijc.2910450132","volume":"45","author":"N Hole","year":"1990","unstructured":"Hole, N. & Stern, P. L. Isolation and characterization of 5T4, a tumour-associated antigen. Int. J. Cancer 45, 179\u2013184 (1990).","journal-title":"Int. J. Cancer"},{"key":"BFncomms14834_CR24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/mt.2009.278","volume":"18","author":"RA Barraza","year":"2010","unstructured":"Barraza, R. A. et al. Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure. Mol. Ther. 18, 491\u2013501 (2010).","journal-title":"Mol. Ther."},{"key":"BFncomms14834_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1021\/pr050276b","volume":"5","author":"AC Saphire","year":"2006","unstructured":"Saphire, A. C., Gallay, P. A. & Bark, S. J. Proteomic analysis of human immunodeficiency virus using liquid chromatography\/tandem mass spectrometry effectively distinguishes specific incorporated host proteins. J. Proteome Res. 5, 530\u2013538 (2006).","journal-title":"J. Proteome Res."},{"key":"BFncomms14834_CR26","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1002\/pmic.200800747","volume":"9","author":"J Denard","year":"2009","unstructured":"Denard, J. et al. Quantitative proteomic analysis of lentiviral vectors using 2-DE. Proteomics 9, 3666\u20133676 (2009).","journal-title":"Proteomics"},{"key":"BFncomms14834_CR27","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.4049\/jimmunol.168.11.5722","volume":"168","author":"G Greco","year":"2002","unstructured":"Greco, G. et al. Matrix fibronectin increases HIV stability and infectivity. J. Immunol. 168, 5722\u20135729 (2002).","journal-title":"J. Immunol."},{"key":"BFncomms14834_CR28","doi-asserted-by":"publisher","first-page":"8247","DOI":"10.1128\/JVI.00312-07","volume":"81","author":"C Beer","year":"2007","unstructured":"Beer, C. & Pedersen, L. Matrix fibronectin binds gammaretrovirus and assists in entry: new light on viral infections. J. Virol. 81, 8247\u20138257 (2007).","journal-title":"J. Virol."},{"key":"BFncomms14834_CR29","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3390\/toxins2122754","volume":"2","author":"J Kohlsch\u00fctter","year":"2010","unstructured":"Kohlsch\u00fctter, J., Michelfelder, S. & Trepel, M. Novel cytotoxic vectors based on adeno-associated virus. Toxins 2, 2754\u20132768 (2010).","journal-title":"Toxins"},{"key":"BFncomms14834_CR30","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1038\/mtna.2014.2","volume":"3","author":"X Wang","year":"2014","unstructured":"Wang, X. et al. R88-APOBEC3Gm inhibits the replication of both drug-resistant strains of HIV-1 and viruses produced from latently infected cells. Mol. Ther. Nucleic Acids 3, e151 (2014).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"BFncomms14834_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/v6010243","volume":"6","author":"E Chan","year":"2014","unstructured":"Chan, E., Towers, G. J. & Qasim, W. Gene therapy strategies to exploit TRIM derived restriction factors against HIV-1. Viruses 6, 243\u2013263 (2014).","journal-title":"Viruses"},{"key":"BFncomms14834_CR32","doi-asserted-by":"publisher","first-page":"6577","DOI":"10.1128\/JVI.79.11.6577-6587.2005","volume":"79","author":"R Cantin","year":"2005","unstructured":"Cantin, R., M\u00e9thot, S. & Tremblay, M. J. Plunder and stowaways: incorporation of cellular proteins by enveloped viruses. J. Virol. 79, 6577\u20136587 (2005).","journal-title":"J. Virol."},{"key":"BFncomms14834_CR33","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/jgm.1022","volume":"9","author":"DC Farley","year":"2007","unstructured":"Farley, D. C. et al. Factors that influence VSV-G pseudotyping and transduction efficiency of lentiviral vectors-in vitro and in vivo implications. J. Gene Med. 9, 345\u2013356 (2007).","journal-title":"J. Gene Med."},{"key":"BFncomms14834_CR34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1089\/088282403771926283","volume":"16","author":"SA Steer","year":"2003","unstructured":"Steer, S. A. & Corbett, J. A. The role and regulation of COX-2 during viral infection. Viral Immunol. 16, 447\u2013460 (2003).","journal-title":"Viral Immunol."},{"key":"BFncomms14834_CR35","first-page":"469","volume":"39","author":"EJ Lee","year":"2007","unstructured":"Lee, E. J. et al. Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells. Mol. Med. 39, 469\u2013476 (2007).","journal-title":"Mol. Med."},{"key":"BFncomms14834_CR36","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1038\/mtna.2012.48","volume":"1","author":"H Chen","year":"2012","unstructured":"Chen, H. Exploiting the intron-splicing mechanism of insect cells to produce viral vectors harboring toxic genes for suicide gene therapy. Mol. Ther. Nucleic Acids 1, e57 (2012).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"BFncomms14834_CR37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/bit.24342","volume":"109","author":"MG Cottingham","year":"2012","unstructured":"Cottingham, M. G. et al. Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. Biotechnol. Bioeng. 109, 719\u2013728 (2012).","journal-title":"Biotechnol. Bioeng."},{"key":"BFncomms14834_CR38","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/mt.2015.123","volume":"23","author":"B Strobel","year":"2015","unstructured":"Strobel, B. et al. Riboswitch-mediated attenuation of transgene cytotoxicity increases adeno-associated virus vector yields in HEK-293 cells. Mol. Ther 23, 1582\u20131591 (2015).","journal-title":"Mol. Ther"},{"key":"BFncomms14834_CR39","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1261\/rna.034744.112","volume":"18","author":"LA Heinicke","year":"2012","unstructured":"Heinicke, L. A. & Bevilacqua, P. C. Activation of PKR by RNA misfolding: HDV ribozyme dimers activate PKR. RNA 18, 2157\u20132165 (2012).","journal-title":"RNA"},{"key":"BFncomms14834_CR40","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jgm.209","volume":"3","author":"W Tabotta","year":"2001","unstructured":"Tabotta, W., Klein, D., Hohenadl, C., Salmons, B. & G\u00fcnzburg, W. H. Genetic reshuffling reconstitutes functional expression cassettes in retroviral vectors. J. Gene Med. 3, 418\u2013426 (2001).","journal-title":"J. Gene Med."},{"key":"BFncomms14834_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/jgm.1143","volume":"10","author":"EM Brandtner","year":"2008","unstructured":"Brandtner, E. M. et al. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches. J. Gene Med. 10, 113\u2013122 (2008).","journal-title":"J. Gene Med."},{"key":"BFncomms14834_CR42","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/sj.mt.6300062","volume":"15","author":"JD Burke","year":"2007","unstructured":"Burke, J. D. & Morris, J. C. Retroviral vectors encoding a reverse transcription-activated transgene efficiently limit expression of the gene to target cells. Mol. Ther. 15, 552\u2013559 (2007).","journal-title":"Mol. Ther."},{"key":"BFncomms14834_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2144\/000114178","volume":"56","author":"C Bagnis","year":"2014","unstructured":"Bagnis, C., Zwojsczyki, G., Chiaroni, J. & Bailly, P. Off-on polyadenylation strategy as a supplemental mechanism for silencing toxic transgene expression during lentiviral vector production. Biotechniques 56, 311\u2013312 (2014).","journal-title":"Biotechniques"},{"key":"BFncomms14834_CR44","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","volume":"383","author":"S Palfi","year":"2014","unstructured":"Palfi, S. et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1\/2 trial. Lancet 383, 1138\u20131146 (2014).","journal-title":"Lancet"},{"key":"BFncomms14834_CR45","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/S0076-6879(02)46072-7","volume":"346","author":"JB Rohll","year":"2002","unstructured":"Rohll, J. B. et al. Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors. Methods Enzymol. 346, 466\u2013500 (2002).","journal-title":"Methods Enzymol."},{"key":"BFncomms14834_CR46","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/JVI.72.1.811-816.1998","volume":"72","author":"VN Kim","year":"1998","unstructured":"Kim, V. N., Mitrophanous, K. A., Kingsman, S. M. & Kingsman, A. J. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 72, 811\u2013816 (1998).","journal-title":"J. Virol."},{"key":"BFncomms14834_CR47","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.1128\/JVI.74.10.4839-4852.2000","volume":"74","author":"E Kotsopoulou","year":"2000","unstructured":"Kotsopoulou, E., Kim, V. N., Kingsman, A. J., Kingsman, S. M. & Mitrophanous, K. A. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J. Virol. 74, 4839\u20134852 (2000).","journal-title":"J. Virol."},{"key":"BFncomms14834_CR48","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0304-4165(00)00165-3","volume":"1524","author":"DM Shaw","year":"2000","unstructured":"Shaw, D. M. et al. Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4. Biochim. Biophys. Acta 1524, 238\u2013246 (2000).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFncomms14834_CR49","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nmeth.1322","volume":"6","author":"JR Wi\u015bniewski","year":"2009","unstructured":"Wi\u015bniewski, J. R., Zougman, A., Nagaraj, N. & Mann, M. Universal sample preparation method for proteome analysis. Nat. Methods 6, 359\u2013362 (2009).","journal-title":"Nat. Methods"},{"key":"BFncomms14834_CR50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nbt.1592","volume":"28","author":"NM Griffin","year":"2010","unstructured":"Griffin, N. M. et al. Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis. Nat. Biotechnol. 28, 83\u201389 (2010).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms14834.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms14834","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncomms14834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms14834.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T19:28:25Z","timestamp":1671737305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms14834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,27]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,4,28]]}},"alternative-id":["BFncomms14834"],"URL":"https:\/\/doi.org\/10.1038\/ncomms14834","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,27]]},"assertion":[{"value":"16 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The work described was fully funded by Oxford BioMedica Ltd., and all authors at the time of submission, except T.T.M. and S.T., were employees and hold stock or stock options within the company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14834"}}